BioSpace News Archive

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2022.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended June 30, 2022.

Timber Pharmaceuticals, Inc. announced the closing of its previously announced public offering of 66,666,667 shares of its common stock and warrants to purchase up to 66,666,667 shares of its common stock at an offering price to the public of $0.12 per share and associated warrant.

Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights.

Forecast to 2030,’ thoroughly examines the Inguinal Hernia Device industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Morquio Syndrome industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Prostate Cancer industry to provide essential data & information for the targeted readers.

The global Radiotherapy Market is expected to reach USD 7.65 Billion by 2027, according to a new report by Emergen Research.

Forecast to 2030,’ thoroughly examines the Tardive Dyskinesia industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Restless Leg Syndrome industry to provide essential data & information for the targeted readers.